patent.fyi
Applications  /  US 2026/0356795
United States Patent Application Publication

US 2026/0356795 A1

Published
Nov 12, 2026
Filed
Apr 28, 2026
Earliest date on the face
Apr 28, 2025
Classification
C07C 229/48
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Cyclopropyl group at R

What ifWhat if R is a cyclopropyl group attached through one ring carbon?
Claim language“R is C1-C6-alkyl, C2-C6-alkenyl, or C2-C6-alkynyl”

The three ring carbons form a compact hydrophobic group next to the attachment point. Ring closure fixes the two carbon paths from that point relative to each other.

1.1Phenyl group at R

What ifWhat if R is a phenyl group attached through one aromatic carbon?
Claim language“R is C1-C6-alkyl, C2-C6-alkenyl, or C2-C6-alkynyl”

The six aromatic carbons form a rigid, planar surface. That surface provides a hydrophobic contact area and a π system for interactions with aromatic side chains in a binding pocket.

1.1Methoxy group at R

What ifWhat if R is a methoxy group attached through its oxygen atom?
Claim language“R is C1-C6-alkyl, C2-C6-alkenyl, or C2-C6-alkynyl”

The ether oxygen supplies a hydrogen-bond acceptor at the attachment point. The methyl carbon provides a small hydrophobic surface one bond farther out.

1.2Terminal nitrile on the chain

What ifWhat if the alkyl chain carries a terminal cyano group?
Claim language“halogen or hydroxyl”

A 2-cyanoethyl group places the nitrile nitrogen two methylene units from the attachment point. The linear nitrile supplies a local dipole and a hydrogen-bond acceptor at the end of the chain.

1.2Terminal ether on the chain

What ifWhat if the alkyl chain carries a terminal methoxy substituent?
Claim language“halogen or hydroxyl”

A 2-methoxyethyl group places an ether oxygen between the second methylene carbon and a terminal methyl carbon. The oxygen accepts hydrogen bonds from water or a donor group in a binding pocket.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Deuterated methyl side chain

A trideuteromethyl group, –CD₃, replaces the protium methyl group, –CH₃, at the R position. The cyclopentane stereochemistry, difluoromethylenyl group, amine, and carboxylic acid retain the same arrangement. Liquid chromatography–mass spectrometry distinguishes the two forms by a mass difference of approximately 3.019 daltons when both are present in a sample.

Cyclopropyl group at the R position

A cyclopropyl group replaces a propyl group at the R position through a direct bond between a ring carbon and the same scaffold attachment site. The substitution retains three side-chain carbons and constrains their geometry within a three-membered ring. A paired enzyme assay measures residual γ-aminobutyric acid aminotransferase activity for the cyclopropyl and propyl forms under matched concentration and preincubation conditions.

Parameter or scale variation

Microwell time course for enzyme inactivation

A 384-well plate holds 20 microliters of purified γ-aminobutyric acid aminotransferase and test compound per preincubation well at 25 °C. Replicate wells use compound concentrations of 0, 0.1, 1, 10, and 100 micromolar and preincubation times of 0, 5, 15, and 30 minutes. At each endpoint, a 2-microliter aliquot enters 38 microliters of substrate and detection mixture, and its initial reaction rate is compared with that of a time-matched vehicle control.

Combination with existing systems

Enzyme assay coupled to mass spectrometry

A liquid chromatograph coupled to a tandem mass spectrometer measures succinic semialdehyde in enzyme reactions containing the inactivator. An autosampler injects quenched aliquots containing an isotopically labeled succinic semialdehyde internal standard. The instrument separates the analyte from the reaction matrix, and the analyte-to-standard peak area ratio gives product concentration against a calibration curve.

Automated or data-driven variant

Automated fitting of inactivation rates

A liquid handler prepares compound dilutions and starts staggered preincubations with purified γ-aminobutyric acid aminotransferase. A plate reader records initial rates from a coupled succinic semialdehyde dehydrogenase assay, and software normalizes them to time-matched vehicle controls. The software fits activity versus preincubation time at each concentration and reports apparent inactivation rates with confidence intervals.

Specific version of a part

Terminal alkyne at R

R is prop-2-yn-1-yl, a three-carbon group attached through a methylene carbon. The carbon–carbon triple bond constrains the geometry of the terminal segment.

Terminal fluorine on ethyl

R is 2-fluoroethyl, a two-carbon alkyl group with fluorine bonded to its terminal carbon. The terminal carbon is a fluoromethylene unit with a polar carbon–fluorine bond.

Terminal hydroxyl on propyl

R is 3-hydroxypropyl, a three-carbon alkyl group ending in a primary alcohol. The hydroxyl group donates and accepts hydrogen bonds.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,256,218 B2
Published
Aug 14, 2007
Filed
Nov 18, 2003
Document BUS 9,562,031 B1
Published
Feb 7, 2017
Filed
Sep 12, 2015
Class
C07D 317/46
Claim 1
Document A
Document B
1.1R is C1-C6-alkyl, C2-C6-alkenyl, or C2-C6-alkynyl
In certain embodiments of the formula I or formula XIII compounds, the R3a and R3b groups may be lower alkyl, lower alkenyl, or lower alkynyl, or taken together form a cycloalkyl or spiroalkyl group.
A · US 7,256,218 B2 · ¶ 147
The term “alkoxy” as used herein by itself or as part of another substituent, refers to the group —OR, wherein R is a lower alkyl, lower alkenyl, or lower alkynyl group as defined herein, which may also be written as C1-C5 alkyl, C2-C5 alkenyl, and C2-C5 alkynyl, respectively.
B · US 9,562,031 B1 · ¶ 62
1.2wherein the C1-C6-alkyl is optionally substituted with halogen or hydroxyl.
The term “alkylthio” as used herein by itself or as part of another substituent, refers to a group —SR, wherein R is a lower alkyl group as defined herein, which can also be written as C1-C5 alkyl.
B · US 9,562,031 B1 · ¶ 88

An empty cell means only that no passage was reproduced there.

Statements in these documents
These triazine derivatives must be administered by injection to observe activity comparable to or exceeding other known antimalarial drugs and are poorly tolerated when given by the oral route.
A · US 7,256,218 B2 · ¶ 3
More specifically, the present invention relates to biguanide and dihydrotriazine derivatives, compositions containing biguanide and dihydrotriazine derivatives, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents, and methods of making the biguanide and dihydrotriazine derivatives.
A · US 7,256,218 B2 · ¶ 2
Thus, there is a need for new chemotherapeutic agents for use as both monotherapies and for combination with new targeted therapies.
B · US 9,562,031 B1 · ¶ 4
The present invention generally relates to phenethyldihydrobenzodioxolone compounds and compositions useful for reducing or inhibiting tumor growth.
B · US 9,562,031 B1 · ¶ 2
Cite aspatent.fyi, US 2026/0356795 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356795/, SHA-256 d8e059199dabda7d5c2840654a87971280eae77b798436ace025c97f1d08cb56
First published
Permanent addresshttps://patent.fyi/US20260356795/
Content fingerprint (SHA-256)d8e059199dabda7d5c2840654a87971280eae77b798436ace025c97f1d08cb56
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi